Journal: Oncotarget

Article Title: CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma

doi: 10.18632/oncotarget.24191

Figure Lengend Snippet: ( A ) Schematic genome organization of the applied oncolytic viruses. Asterisks indicate the mutated residues in H protein to achieve blinding for the natural MV receptors CD46 and SLAM. The coding sequence for the CD30-specific scFv together with a C-terminal hexa-His-tag (H6) is fused to H mut . In VSV-CD30 the glycoprotein (G) reading frame was replaced with those of MV-F and H mut -CD30scFv ( B ) Immunoblot of virus stocks using rabbit-α-VSV serum (left panel) or antibodies recognizing the cytoplasmic tail of MV-H (center and right panel top row) or MV-F (center and right panel bottom row). ( C ) Multi-step growth curves of CD30-targeted viruses and untargeted parental viruses on Vero-αHis cells of cell-associated (lysate) and supernatant (SN) virus after infection at a multiplicity of infection (MOI) of 0.3, respectively. Titers were determined as 50% tissue culture infective dose (TCID50). n = 2, error bars: mean ± SD.

Article Snippet: Expression of human CD30 was detected by a phycoerythrin (PE)-labeled mouse CD30 antibody (clone: Ki-2, Miltenyi Biotech, Germany).

Techniques: Sequencing, Western Blot, Virus, Infection

Journal: Oncotarget

Article Title: CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma

doi: 10.18632/oncotarget.24191

Figure Lengend Snippet: ( A ) CHO-cells stably expressing SLAM, CD46 or CD30 were infected with CD30-targeted viruses or untargeted parental viruses at an MOI of 1 and analyzed by fluorescence microscopy 24 h (VSV-MV, VSV-CD30) or 72 h (MV, MV-CD30) post infection, respectively. Scale bar = 200 μm. ( B ) HT1080-RFP and HT1080-CD30 were co-cultured at a ratio of 70:30 and infected with CD30-targeted viruses or untargeted parental viruses at an MOI of 1 and analyzed by fluorescence microscopy 24 h (VSV-MV, VSV-CD30) or 72 h (MV, MV-CD30) post infection, respectively. An overlay of red and green fluorescence is shown. Scale bar = 200 μm. (C) VSV-MV and VSV-CD30 were pre-incubated for 30 min with increasing amounts of CD30-Fc protein. Subsequently, HT1080-CD30 cells were inoculated and the percentages of infected cells were determined 72 h later. Relative infectivities were calculated by normalizing the values to mock treated controls. n = 3, error bars: mean ± SD.

Article Snippet: Expression of human CD30 was detected by a phycoerythrin (PE)-labeled mouse CD30 antibody (clone: Ki-2, Miltenyi Biotech, Germany).

Techniques: Stable Transfection, Expressing, Infection, Fluorescence, Microscopy, Cell Culture, Incubation

Journal: Oncotarget

Article Title: CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma

doi: 10.18632/oncotarget.24191

Figure Lengend Snippet: ( A ) FACS analysis of the human cHL cell lines L-428, L-1236 and KM-H2 for expression of CD30, SLAM and CD46. ( B ) The cHL cell lines L-428, L-1236 and KM-H2 were infected with the CD30-targeted or the untargeted parental viruses at an MOI of 1, respectively, and analyzed by fluorescence microscopy 24 h (VSV-MV, VSV-CD30) or 72 h (MV, MV-CD30) post infection. Scale bar = 200 μm. ( C ) Cell viability was determined using the RealTime-Glo MT Cell Viability Assay. Human KM-H2 cells were infected with MV-CD30 or VSV-CD30 an MOI of 1, respectively, and viability was determined until 48 h post infection. n = 3, Error bars: mean ± SD.

Article Snippet: Expression of human CD30 was detected by a phycoerythrin (PE)-labeled mouse CD30 antibody (clone: Ki-2, Miltenyi Biotech, Germany).

Techniques: Expressing, Infection, Fluorescence, Microscopy, Viability Assay

Journal: Oncotarget

Article Title: CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma

doi: 10.18632/oncotarget.24191

Figure Lengend Snippet: KM-H2 cells were implanted subcutaneously into NSG mice. 13 days post cell implantation, mice received three intratumoral injections over a period of five days (dotted lines) covering a total dose of 3 × 10 6 TCID50 (MV-CD30, VSV-CD30 low dose) or 3 × 10 8 TCID50 (VSV-CD30 high dose). ( A ) Tumor growth curves of MV-CD30 (blue circles), VSV-CD30 low dose (purple triangles), VSV-CD30 high dose (red triangles, +) or mock (black rectangles) treated mice. ( B ) Calculated area under the curve (AUC) values for tumor growth data shown in (A). One-way ANOVA test (Multiple comparisons), **** p < 0.0001. ( C ) Kaplan-Meier plot survival analysis. Logrank test (Bonferroni adjusted), *** p < 0.001, ** p < 0.01. Measles virus (MV)-CD30, n = 7; vesicular stomatitis virus (VSV)-CD30 low dose, n = 8; VSV-CD30 high dose, n = 8; mock, n = 8. Error bars: mean ± SEM.

Article Snippet: Expression of human CD30 was detected by a phycoerythrin (PE)-labeled mouse CD30 antibody (clone: Ki-2, Miltenyi Biotech, Germany).

Techniques: Virus

Journal: Oncotarget

Article Title: CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma

doi: 10.18632/oncotarget.24191

Figure Lengend Snippet: ( A ) KM-H2 cells were implanted subcutaneously into NSG mice. 14 days post cell implantation, a total dose of 3 × 10 8 TCID50 of VSV-CD30 split in three aliquots was systemically injected weekly (dotted lines). Tumor growth curves of VSV-CD30 (red triangles) or mock (black rectangles) treated mice are shown. ( B ) Calculated area under the curve (AUC) values for tumor growth data shown in (A). Unpaired t test, **** p < 0.0001. Vesicular stomatitis virus (VSV)-CD30, n = 7; mock, n = 8. Error bars: mean ± SEM. ( C ) KM-H2-luc cells were injected intravenously into NSG mice. Based on the luciferase signal intensity on day 14, mice received three intravenous injections of VSV-CD30 covering a total dose of 3 × 10 8 TCID50 on day 18, 21 and 28 post cell administration. Quantified luciferase signals on day 46 are shown as logarithm of the total flux (p/sec). Unpaired T test, p = 0.07. VSV-CD30, n = 8; mock, n = 6.

Article Snippet: Expression of human CD30 was detected by a phycoerythrin (PE)-labeled mouse CD30 antibody (clone: Ki-2, Miltenyi Biotech, Germany).

Techniques: Injection, Virus, Luciferase

Journal: BioMed Research International

Article Title: CD30 Is Highly Expressed in Chronic Obstructive Pulmonary Disease and Induces the Pulmonary Vascular Remodeling

doi: 10.1155/2018/3261436

Figure Lengend Snippet: The level of CD30 and CD30L in serum from the patients with stable COPD and AECOPD. ((a) and (b)) The level of CD30L and sCD30 in serum from stable COPD and AECOPD and the normal group. Columns, mean of the group; bars, SD. ∗ P < 0.05, normal group versus AECOPD group. # P < 0.05, stable COPD group versus AECOPD group.

Article Snippet: CD30 antibody from Bioss Antibodies (Beijing, China), CD30L antibody purchased from Boster Biological Technology (Wu Han, China).

Techniques:

Journal: BioMed Research International

Article Title: CD30 Is Highly Expressed in Chronic Obstructive Pulmonary Disease and Induces the Pulmonary Vascular Remodeling

doi: 10.1155/2018/3261436

Figure Lengend Snippet: Immunohistochemical analysis of CD30, CD30L, MMP-9, and VEGF expression in rat models. (A) The expression levels of CD30, CD30L, MMP-9, and VEGF in lung tissues of rat model groups were determined by IHC. CTR: control group; NTR: negative control group. IHC ×200.

Article Snippet: CD30 antibody from Bioss Antibodies (Beijing, China), CD30L antibody purchased from Boster Biological Technology (Wu Han, China).

Techniques: Immunohistochemical staining, Expressing, Control, Negative Control